Chairman of the Novo Nordisk Foundation, which owns more than a quarter of Novo Nordisk's shares. Mr Sørensen ran Novo before Lars Fruergaard Jørgensen. After the board ousted Mr Jørgensen in 2025, he rebuked it for being "too slow" to grasp the shifts in the market for weight-loss drugs. Following a subsequent purge in which seven board members resigned, he took over as the drugmaker's chairman.
Never explain. Your friends do not need it and your enemies will never believe you anyway.